Literature DB >> 18313914

Could polymorphisms in ATP-binding cassette C3/multidrug resistance associated protein 3 (ABCC3/MRP3) modify colorectal cancer risk?

Daniele Campa1, Pavel Vodicka, Barbara Pardini, Jan Novotny, Asta Försti, Kari Hemminki, Roberto Barale, Federico Canzian.   

Abstract

Multidrug resistance associated protein 3 (ABCC3/MRP3) mediates the efflux of bile salts and several conjugated organic anions out of cells and could be involved in protecting tissues from xenobiotic accumulation and resulting toxicity. In this report, we investigated the hypothesis that a functional missense variant, namely the Arg1297His, and a polymorphism in the promoter region, namely the -211 C>T of the ABCC3 gene, could be associated with colorectal cancer risk. We did not find any significant association between the two ABCC3 polymorphisms and colorectal cancer risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313914     DOI: 10.1016/j.ejca.2008.02.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children.

Authors:  Raja Venkatasubramanian; Tsuyoshi Fukuda; Jing Niu; Tomoyuki Mizuno; Vidya Chidambaran; Alexander A Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2014-07       Impact factor: 2.533

2.  Association of pregnane X receptor with multidrug resistance-related protein 3 and its role in human colon cancer chemoresistance.

Authors:  Heng Jiang; Keli Chen; Jianming He; Feng Pan; Jianjun Li; Jianfang Chen; Wensheng Chen; Houjie Liang
Journal:  J Gastrointest Surg       Date:  2009-07-11       Impact factor: 3.452

3.  A gene-wide investigation on polymorphisms in the taste receptor 2R14 (TAS2R14) and susceptibility to colorectal cancer.

Authors:  Daniele Campa; Pavel Vodicka; Barbara Pardini; Alessio Naccarati; Maura Carrai; Ludmila Vodickova; Jan Novotny; Kari Hemminki; Asta Försti; Roberto Barale; Federico Canzian
Journal:  BMC Med Genet       Date:  2010-06-09       Impact factor: 2.103

4.  Polymorphisms of genes coding for ghrelin and its receptor in relation to colorectal cancer risk: a two-step gene-wide case-control study.

Authors:  Daniele Campa; Barbara Pardini; Alessio Naccarati; Ludmila Vodickova; Jan Novotny; Verena Steinke; Nils Rahner; Elke Holinski-Feder; Monika Morak; Hans K Schackert; Heike Görgens; Judith Kötting; Beate Betz; Matthias Kloor; Christoph Engel; Reinhard Büttner; Peter Propping; Asta Försti; Kari Hemminki; Roberto Barale; Pavel Vodicka; Federico Canzian
Journal:  BMC Gastroenterol       Date:  2010-09-28       Impact factor: 3.067

5.  Association between TAS2R38 gene polymorphisms and colorectal cancer risk: a case-control study in two independent populations of Caucasian origin.

Authors:  Maura Carrai; Verena Steinke; Pavel Vodicka; Barbara Pardini; Nils Rahner; Elke Holinski-Feder; Monika Morak; Hans K Schackert; Heike Görgens; Susanne Stemmler; Beate Betz; Matthias Kloor; Christoph Engel; Reinhard Büttner; Alessio Naccarati; Ludmila Vodickova; Jan Novotny; Angelika Stein; Kari Hemminki; Peter Propping; Asta Försti; Federico Canzian; Roberto Barale; Daniele Campa
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

6.  Association between polymorphisms of TAS2R16 and susceptibility to colorectal cancer.

Authors:  Jonathan Barontini; Marco Antinucci; Sergio Tofanelli; Maurizio Cammalleri; Massimo Dal Monte; Federica Gemignani; Pavel Vodicka; Roberto Marangoni; Ludmila Vodickova; Juozas Kupcinskas; Veronika Vymetalkova; Asta Forsti; Federico Canzian; Angelika Stein; Victor Moreno; Nicola Mastrodonato; Francesca Tavano; Anna Panza; Roberto Barale; Stefano Landi; Daniele Campa
Journal:  BMC Gastroenterol       Date:  2017-09-15       Impact factor: 3.067

7.  Effect of ABCB1 polymorphism on the clinical outcome of osteosarcoma patients after receiving chemotherapy.

Authors:  Sun Xiaohui; Li Aiguo; Geng Xiaolin; Liu Ying; Zhao Hongxing; Zhao Yilei
Journal:  Pak J Med Sci       Date:  2014-07       Impact factor: 1.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.